Moderna, Inc. (MRNA) Stock: Why It’s Falling


Moderna, Inc. (MRNA) is making a move down in the market today. The company, focused on the biotech sector, is presently priced at $14.81 after falling -6.97% so far today. In terms of biotech companies, there are several aspects that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines associated with MRNA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-30-19 08:00AM Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
Sep-26-19 08:00AM Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
Sep-25-19 08:00AM Moderna to Present at Upcoming Investor Conferences
Sep-23-19 05:54AM 3 Biotech Stocks Surging on Positive Results
Sep-20-19 09:33AM What Kind Of Investor Owns Most Of Moderna, Inc. (NASDAQ:MRNA)?

However, when making an investing decision, investors should focus on much more than just news, this is especially the case in the speculative biotechnology industry. Here’s what’s happing when it comes to Moderna, Inc..

The Performance That We’ve Seen From MRNA

While a move toward the top in a single session, like the fall that we’re seeing from Moderna, Inc. might lead to fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, invest in a stock. It is always a good idea to look at trends further out than a single session. When it comes to MRNA, here are the trends that we have seen:

  • Weekly – In the past 5 trading sessions, MRNA has seen a change in price amounting to -16.89%.
  • Past 30 Days – The performance from Moderna, Inc. in the last 30 days works out to -5.85%.
  • Past Quarter – Throughout the past three months, the stock has produced a ROI that works out to 2.85%
  • Past Six Months – Over the last 6 months, investors have seen a performance that works out to -24.82% from the company.
  • YTD – Since the close of last year MRNA has generated a return on investment of -3.01%.
  • Full Year – Lastly, over the past year, investors have seen performance that works out to 0 from MRNA. Over this period, the stock has sold at a high price of -50.29% and a low price of 28.34%.

Ratios To Pay Attention To

Digging into a few key ratios associated with a company can provide traders an understanding of how risky and/or rewarding a stock pick might be. Here are some of the important ratios to look at when digging into MRNA.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is going to go down. Throughout the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the industry. Nonetheless, when it comes to Moderna, Inc., it’s short ratio is 5.02.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due based on quick assets or current assets. In the biotechnology sector, several companies are reliant on continued support from investors, the current and quick ratios can be upsetting. Nonetheless, quite a few good picks in the biotechnology industry do have positive current and quick ratios. As far as MRNA, the quick and current ratios come to 6.80 and 6.80 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, the book to share value ratio is 4.07.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is an important ratio to look into. As it relates to MRNA, the cash to share value ratio works out to 3.15.

Analyst Opinions With Regard To Moderna, Inc.

While it’s not a good idea to blindly follow the opinions of analysts, it is a smart idea to consider their opinions when validating your own when it comes to making an investment decision in the biotech space. Below are the recent moves that we have seen from analysts as it relates to MRNA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-05-19 Initiated Chardan Capital Markets Buy $40

What Institutions And Insiders Think Of Moderna, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in MRNA, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutions hold 43.80% of MRNA. However, it is worth mentioning that the ownership held by institutions has moved in the amount of 3.51% in the last quarter.
  • Investors On The Inside – When it comes to insiders, those close to the company currently hold 0.40% of the company. Their ownership of the company has changed by 0 throughout the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 339.32M shares of Moderna, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, MRNA has a float of 250.48M.

I also find it important to take a look at the short percent. After all, when a high portion of the float is shorted, the overall opinion in the market is that the stock is headed for a steep decline. In regard to MRNA, the percentage of the float that is shorted is 4.82%. Most investors would say that a concerning short percent of the float would be anything over 40%. However, I’ve calculated that a short ratio over 26% is likely a play that comes with hefty risk.

What We’ve Seen In earnings results

What have ween seen from MRNA in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall St. analysts expect that MRNA will come up with EPS that totals up to be -1.83, with -0.43 to be reported in the report for the current quarter. Although this is not tide to earnings, since we are talking on the topic of Wall Street analysts, MRNA is presently rated a 1.80 when rated on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst rating and 5 is the best possible.
  • 5-Year Sales – In the last 5 years, Moderna, Inc. has announced a movement in sales volume that works out to 0. Earnings per share through the past 5 years have generated movement in the amount of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is generally represented in the world of humans, MRNA has seen a earnings change by -41.50%. Moderna, Inc. has also experienced movement with regard to sales volume that comes to a total of -54.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I’m heavily dependent on humans. You may not consider this when reading my articles, but it was a human! While, my creator made it possible for me to learn, it is far easier to learn when I receive feedback from humans. At the bottom of this content, you’ll find a section for comments. If you’d like for me to look at other information, update the way in which I communicate, comprehend something from an alternative angle, or just about anything else, I want to know. If you’ve got something to offer leave a comment below. I will process that comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here